PQCA

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

PQCA 是一种高度选择性且有效的毒蕈碱 M1 受体阳性变构调节剂。PQCA 在恒河猴和人 M1 受体上的 EC50 值分别为 49 nM 和 135 nM，并对其他毒蕈碱受体无活性。PQCA 具有减少与阿尔茨海默氏病相关的认知缺陷的潜力。

PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC50 value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively.PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease.

——

PQCA (3-30 mg/kg; oral administration; single- or pair-housed male rhesus monkeys) treatment attenuates the scopolamine deficits in PAL and CPT tasks. Blockade of muscarinic signaling by scopolamine produces significant impairments in both tasks.Animal Model:Ten single- or pair-housed male rhesus monkeys (6-10 years old; 5.2-10.5 kg) with scopolamine Dosage:3 mg/kg, 10 mg/kg, or 30 mg/kg Administration:Oral administration Result:Attenuated the scopolamine deficits in paired-associates learning (PAL) and the continuous-performance task (CPT).

——

Cell Cycle/DNA Damage

AChR

AChR

——

——

1144504-35-7

388.42

C22H20N4O3

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 10 mg/mL (25.75 mM; 超声助溶 (<80°C)

OC(=O)c1cc(CN2CCC(CC2)(C#N)c2ccccn2)c2ccccn2c1=O

——

(-20℃)

With Ice Pack

≥ 2 years